Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27003914
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Current Status: Site-Specific Antibody Drug Conjugates
#MMPMID27003914
Schumacher D
; Hackenberger CP
; Leonhardt H
; Helma J
J Clin Immunol
2016[May]; 36 Suppl 1
(?): 100-7
PMID27003914
show ga
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals,
combine the specificity of therapeutic antibodies with the pharmacological
potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a
plethora of novel ADC technologies has emerged, covering as diverse aspects as
antibody engineering, chemical linker optimization and novel conjugation
strategies, together aiming at constantly widening the therapeutic window for
ADCs. This review primarily focuses on novel chemical and biotechnological
strategies for the site-directed attachment of drugs that are currently validated
for 2nd generation ADCs to promote conjugate homogeneity and overall stability.
free
free
free
